Tag: IRB IEC

Under-Representation of Specific Demographics: Identifying and Addressing Gaps

November 14, 2025November 14, 2025 digi

Under-Representation of Specific Demographics: Identifying and Addressing Gaps The global landscape of clinical research is rapidly evolving as regulatory authorities and stakeholders increasingly recognize the importance of diversity in clinical trials. Under-representation of specific demographics, particularly in clinical research related to conditions such as schizophrenia, poses significant ethical and scientific challenges. This comprehensive guide offers…

Equity in Recruitment & Fair Participant Selection

Payment Methods and Timing: Operationalizing Ethics Committee Guidance

November 14, 2025November 14, 2025 digi

Payment Methods and Timing: Operationalizing Ethics Committee Guidance In the ever-evolving landscape of clinical trial management, understanding and implementing the ethical guidance provided by regulatory authorities is crucial for clinical operations, regulatory affairs, and medical affairs professionals. This comprehensive guide aims to elucidate the operationalization of ethics committee guidance, especially focusing on compensation, reimbursement, and…

Compensation, Reimbursement & Undue Influence

Handling Travel, Time and Lost Wage Reimbursements Across Regions

November 14, 2025November 14, 2025 digi

Handling Travel, Time and Lost Wage Reimbursements Across Regions Handling Travel, Time and Lost Wage Reimbursements Across Regions In clinical trials, particularly those overseen by entities like Sanofi, ensuring proper reimbursement for participants’ travel, time, and lost wages is of paramount importance. This step-by-step guide aims to provide practical insights aimed at clinical operations, regulatory…

Compensation, Reimbursement & Undue Influence

Documenting the Rationale for Payment Models in Protocols and IRB Submissions

November 14, 2025November 14, 2025 digi

Documenting the Rationale for Payment Models in Protocols and IRB Submissions Documenting the Rationale for Payment Models in Protocols and IRB Submissions As clinical trials become increasingly patient-centric, it is essential for clinical research professionals to establish and document sound payment models within protocols and Institutional Review Board (IRB) submissions. Properly addressing compensation structures not…

Compensation, Reimbursement & Undue Influence

Benchmarking Compensation Across Studies and Therapeutic Areas

November 14, 2025November 14, 2025 digi

Benchmarking Compensation Across Studies and Therapeutic Areas Benchmarking Compensation Across Studies and Therapeutic Areas Compensation in clinical research is a multifaceted issue that encompasses ethical considerations, regulatory compliance, and operational logistics. It is essential for clinical operations, regulatory affairs, and medical affairs professionals to establish a fair and transparent compensation framework that addresses the needs…

Compensation, Reimbursement & Undue Influence

Global Differences in Regulations for Vulnerable Subjects: US vs EU vs UK

November 14, 2025November 14, 2025 digi

Global Differences in Regulations for Vulnerable Subjects: US vs EU vs UK Global Differences in Regulations for Vulnerable Subjects: US vs EU vs UK Understanding the regulations surrounding clinical trials involving vulnerable populations is crucial for clinical operations, regulatory affairs, and medical affairs professionals. Vulnerable subjects include children, cognitively impaired individuals, and prisoners, all of…

Vulnerable Populations (Pediatrics, Cognitively Impaired, Prisoners)

Cumulative Burden of Procedures in Pediatric and Cognitively Impaired Populations

November 14, 2025November 14, 2025 digi

Cumulative Burden of Procedures in Pediatric and Cognitively Impaired Populations Cumulative Burden of Procedures in Pediatric and Cognitively Impaired Populations The conduct of clinical trials often requires careful consideration of the populations involved, particularly when these populations are deemed vulnerable. Vulnerable groups, such as pediatric and cognitively impaired individuals, face unique challenges that require tailored…

Vulnerable Populations (Pediatrics, Cognitively Impaired, Prisoners)

Balancing Scientific Value and Participant Protection in Orphan and Rare Disease Trials

November 14, 2025 digi

Balancing Scientific Value and Participant Protection in Orphan and Rare Disease Trials In the context of clinical trials, especially those pertaining to orphan and rare diseases, clinical operations, regulatory affairs, and medical affairs professionals face the intricate challenge of balancing scientific rigor with the ethical obligation to protect vulnerable populations. This guide provides a comprehensive,…

Vulnerable Populations (Pediatrics, Cognitively Impaired, Prisoners)

Data Monitoring Committees for High-Risk and Vulnerable Cohorts

November 14, 2025November 14, 2025 digi

Data Monitoring Committees for High-Risk and Vulnerable Cohorts Data Monitoring Committees for High-Risk and Vulnerable Cohorts In the intricate landscape of clinical trials, the role of Data Monitoring Committees (DMCs) becomes especially critical when dealing with high-risk and vulnerable populations. These groups, which may include pediatrics, individuals with cognitive impairments, and prisoners, require particular attention…

Vulnerable Populations (Pediatrics, Cognitively Impaired, Prisoners)

Vulnerable Populations in Emergency and Critical Care Research

November 14, 2025November 14, 2025 digi

Vulnerable Populations in Emergency and Critical Care Research Vulnerable Populations in Emergency and Critical Care Research Introduction to Vulnerable Populations in Clinical Trials The inclusion of vulnerable populations in clinical trials necessitates a thorough understanding of ethical guidelines and regulatory requirements, particularly in emergency and critical care settings. Vulnerable populations may include children, individuals with…

Vulnerable Populations (Pediatrics, Cognitively Impaired, Prisoners)